samedi 10 octobre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentNasdaq· April 10, 2026

Novel Drugs Approved By The FDA In 2025

View original at nasdaq.com
Novel Drugs Approved By The FDA In 2025 (RTTNews) - The U.S. Food and Drug Administration (FDA) in 2025 approved 46 novel drugs, including 34 new molecular entities (NMEs) and 12 biologics…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

Data points we hold from this source

U.S. Food and Drug Administration · accelerated approvals11 drugs
U.S. Food and Drug Administration · biologics approved12 biologics
U.S. Food and Drug Administration · fast track designations18 drugs
U.S. Food and Drug Administration · first in class drugs20 drugs
U.S. Food and Drug Administration · new molecular entities approved34 NMEs
U.S. Food and Drug Administration · novel drugs approved46 drugs
U.S. Food and Drug Administration · priority reviews21 drugs
U.S. Food and Drug Administration · rare disease drugs23 drugs
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,986
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,986 faits vérifiés avec la source5,366 documents sources archivés
Interrogez ces données → isubstrate.com